Invesco Perpetual
VC Fund
Invesco Perpetual is a VC fund focused on Biotechnology and Medical. Invesco Perpetual
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Invesco Perpetual invests in
Stages Invesco Perpetual invests in
Countries Invesco Perpetual invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Medical 2 (50%)
- Genetics 2 (50%)
- Health Care 2 (50%)
- Biopharma 1 (25%)
Stage
- Series B 1 (25%)
- Series C 1 (25%)
- Venture - Series Unknown 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. | $9.1M / Series B / Dec 09, 2018 | ||
| Genomics plc aiming to lead the genomic transformation of healthcare, to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagramThey will lead the way through this challenge, using their expertise and experience to unleash the potential ofgenomics and set the standards by which organisations and patients can benefit from genomic data. | $32.5M / Series B / Aug 30, 2018 | ||
| Oxford Genetics is a UK-based biotechnology company specializing in the production of versatile cloning plasmids for research in academic and biotechnology institutions. They also provide custom cloning and DNA synthesis. All of their products are free of intellectual property restrictions. | $9.7M / Venture - Series Unknown / Aug 21, 2017 | ||
| Kuur Therapeutics is committed to transforming the lives of patients with cancer and is leading the development of off-the-shelf engineered CAR-NKT cell therapies. Our approach combines the highly differentiated, natural biology of a specific subset of cytotoxic T cells, called natural killer T cells (NKT cells) and innovative CAR constructengineering. In combination, this delivers a very compelling and unique platform, that we believe has the potential to produce many future therapies targeting both hematological and solid tumors. | $73.7M / Series C / Mar 15, 2017 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Invesco Perpetual invest in?
Invesco Perpetual invests primarily in Biotechnology, Medical and Genetics startups, most often at Series B and Series C stage. Most of the 4 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Invesco Perpetual last invest?
The most recent investment recorded for Invesco Perpetual closed in Dec 2018. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
